Virtual Library

Start Your Search

Yong Qian Shu



Author of

  • +

    P81 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy/Immune Checkpoint Inhibitor Single Agent (ID 258)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P81.01 - Efficacy and Safety of Camrelizumab in Patients with Advanced Lung Cancer: A Multicentre, Prospective, Observational Study. (ID 3110)

      00:00 - 00:00  |  Presenting Author(s): Yong Qian Shu

      • Abstract
      • Slides

      Introduction

      Camrelizumab is a humanized PD-1 monoclonal antibody. The efficacy of camrelizumab monotherapy or combined with chemotherapy in treatment of advanced NSCLC had demonstrated promising results in previous studies. However, the efficacy and safety of camrelizumab in treatment of lung cancer in real world is lacking. The main aim of this study was to evaluate the anti-tumor activity and toxicity of camrelizumab in treatment of advanced lung cancer and explore benefit subgroups and optimal regimens.

      Methods

      Eligibility required patients histologically diagnosed with advanced lung cancer and were able to receive treatment regimens based on camrelizumab. The enrolled patients were treated until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoints were adverse events (AE), objective response rate (ORR), disease control rate (DCR), and overall survival (OS).

      Results

      Between August 7, 2019 and July 10, 2020, a total of 222 patients were screened for enrollment and 65 patients reached the primary endpoint. The median age was 64 and 76.6% of them were male. 50.5% of them were adenocarcinoma and 27.5% were squamous carcinoma. SCLC accounted for approximately 14%. 25.2% of them received camrelizumab as first-line therapy, 39.6% as second-line treatment and 35.2% as third- and above-line treatment. Treatment regimens included camrelizumab monotherapy (10.8%), combined with chemotherapy (58.6%), and in combination with anti-angiogenic therapy (24.8%). To the latest date of data collection, 150 pts were accessible for efficacy analysis. 39 (18%), 95(43%), and 16(7%) patients achieved partial response (PR), stable disease (SD), and progression disease(PD), respectively. The ORR was 26% and the DCR was 89.3%. The mPFS was 6.83 months and mOS was not reached. The ORR among male group was 30.4% (95% CI, 22.20%-39.71%), which was significantly higher than in female group, 11.4% (95% CI, 3.20%-26.74%), p=0.04. Patients with ECOG 0 or 1 had significantly higher DCR than whom with ECOG ≥2, 100.00% (95% CI, 76.84%-100.00%), 90.3% (95% CI, 83.71%-94.90%) and 66.7% (95% CI, 34.89%-90.08%), respectively (p=0.02). The main hematological AEs were neutrophil count decreased (15.3%), transaminases elevated (13.5%) andwhite blood cell decreased (13.1%). The main non-hematological AEs were reactive cutaneous capillary hyperplasia (RCCEP, 29.3%) and fatigue (14%). No treatment-related deaths occurred.

      Conclusion

      In real life setting, camrelizumab demonstrated favorable efficacy and tolerable toxicity among patients with advanced lung cancer in China, and we expect follow-up data to provide more clues. [ChiCTR1900026089]

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.